Al Kildani

Al Kildani is the Vice President of Investor Relations and Corporate Communications at Halozyme Therapeutics. Al has over 20 years of experience in the financial industry, with a focus on healthcare.

Kildani began their career as a Senior Research Analyst at Pacific Growth Equities in 1997. In 2003, they joined C.E. Unterberg, Towbin as a Senior Research Analyst. Al left in 2004 to join Stark Investments as Director. Kildani remained with Stark until 2009 when they became a Consultant to the Founder of Kilmer Lucas Inc.

In 2010, Kildani joined Global Hunter Securities as Managing Director of Investment Banking. Al advised emerging growth healthcare companies on capital and strategic matters. Al left Global Hunter in 2011 and joined Hologic as Sr. Director of Investor Relations in 2012. Kildani remained with Hologic until 2014 when they joined Vital Therapies, Inc. as Vice President of Investor Relations and Business Development.

Kildani has been with Halozyme since 2014 and currently serves as Vice President of Investor Relations and Corporate Communications.

The educational career for Al Kildani would be a B.S. in Economics & Finance from Boston College.

Al Kildani reports to Helen Torley , President & CEO. Al Kildani works with Elaine Sun - SVP, CFO, Alison A. Armour - Senior Vice President, Research and Development, and Harry J. Leonhardt - Senior Vice President, General Counsel and Corporate Secretary.